Ceftaroline fosamil: Development discontinued

Dainippon Sumitomo disclosed in its earnings for the fiscal year ended March 31 that it discontinued development of DSP-5990, which was in Phase I testing to treat MRSA infection. The company said the antibiotic did not meet its criteria in a Phase I trial, but did not disclose details. In 2011, Takeda granted Dainippon exclusive rights to develop and commercialize the product in Japan. Dainippon declined to disclose how the discontinuation affects its deal with Takeda. ...